BridgeMD
New treatment option for Post-COVID-19 Syndrome
Official title Transcranial Pulse Stimulation (TPS) in Post-COVID-19
ClinicalTrials.gov ID: NCT06178952
What this study is testing
- What it's testing
- The objective of the present study is to demonstrate treatment efficacy of transcranial pulse stimulation for patients with Post-COVID-19 related neurological symptoms (fatigue, cognitive deficits, mood deterioration). Fatigue, as measured by the Fatigue Impact Scale (FIS), will represent the primary outcome variable.
- You might receive a placebo (an inactive treatment) instead of the study drug, decided by chance. You may not know which one you got.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 20 to 80
You may be able to join if
- Signed written informed consent
- PCR-confirmed SARS-CoV-2 infection, laboratory confirmed antibody detection for SARS-CoV-2, or physician-verified COVID-19 infection
- At least 12 months after initial SARS-CoV-2 infection that led to Post-COVID (subsequent SARS-CoV-2 infections are not a reason for exclusion)
- Diagnosis of Post-COVID Syndrome or independent suspected diagnosis of Post-COVID Syndrome (Considering that physicians generally hesitate to provide...
- Age: 20-80
You likely can't join if
- Clinically relevant realization of pre-COVID diseases with similar symptoms as Post-COVID
- MoCA score \<17 (cut-off for dementia)
- BDI-II score ≥29 (cut-off for severe depression)
- FIS \<10 (cut-off for no fatigue)
- Brain implants
- Non-MR-compatible metal parts in the body
See the full eligibility criteria
- Signed written informed consent
- PCR-confirmed SARS-CoV-2 infection, laboratory confirmed antibody detection for SARS-CoV-2, or physician-verified COVID-19 infection
- At least 12 months after initial SARS-CoV-2 infection that led to Post-COVID (subsequent SARS-CoV-2 infections are not a reason for exclusion)
- Diagnosis of Post-COVID Syndrome or independent suspected diagnosis of Post-COVID Syndrome (Considering that physicians generally hesitate to provide clear-cut Post-COVID diagnoses, a tentative diagnosis by an...
- Age: 20-80
- Evidence of a negative pregnancy test if medically adequate
- Clinically relevant realization of pre-COVID diseases with similar symptoms as Post-COVID
- MoCA score \<17 (cut-off for dementia)
- BDI-II score ≥29 (cut-off for severe depression)
- FIS \<10 (cut-off for no fatigue)
- Brain implants
- Non-MR-compatible metal parts in the body
- Metal parts in the head
- Use of anticoagulants
- Non-MR-compatible claustrophobia
- Non-MR-compatible pacemaker
- Pregnant and breastfeeding women
- Clinically relevant history of surgery on the head, heart, or vessels
- Relevant corticosteroid treatments administered within 6 weeks prior to the first application
- Tumor of the head if relevant for treatment
- Blood clotting disorders
- Participation in other studies
The study team makes the final eligibility decision.
Where it's taking place
- Vienna, State of Vienna, Austria
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 20 years to 80 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Vienna, State of Vienna, Austria. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.